Close Menu

NEW YORK, Oct. 9 – Sequitur has entered into an agreement with Procter and Gamble Pharmaceuticals to provide the company access to its functional genomics technology, the companies announced Tuesday.

Sequitur, based in Natick, Mass., will perform biological screening and supply its proprietary antisense compounds and methods to Procter and Gamble for use in its target validation studies as part of a multi-year agreement, according to the companies. 

Financial details were not disclosed. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.